Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.73 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968447 | 0.84 | MPO (1.00) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL13715806 | 0.84 | MPO (0.81) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL13715343 | 0.83 | MPO (0.73) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL4801899 | 0.83 | MPO (0.73) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL27503238 | 0.83 | MPO (0.73) | MPOSLC6A4GPR84PCSK9HTR2A | |
| Hydrochloric Acid SCHEMBL23091149 | 0.83 | MPO (0.97) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL29005984 | 0.82 | GPR84 (1.00) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL5239539 | 0.81 | MPO (1.00) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL1120483 | 0.79 | GPR84 (0.68) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL25169442 | 0.79 | MPO (0.67) | MPOSLC6A4GPR84HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988377-B2 | Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-05 | — | — | US | disclosed |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2013028999-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | GFRA1, GFRA2, GFRA3 | MPO 1137/4885SLC6A4 178/4885GPR84 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.